Precision BioSciences, Inc. Common Stock

DTILNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
6.97 USD
↗ 0.05 (0.72%)AT CLOSE (11:59 AM EDT)
7.00
↗ 0.03 (0.36%)
POST MARKET (AS OF 07:10 PM EDT)
Post Market
AS OF 07:10 PM EDT
7.00
↗ 0.03 (0.36%)
🔴Market: CLOSED
Open?$6.99
High?$7.13
Low?$6.68
Prev. Close?$6.92
Volume?266.2K
Avg. Volume?258.7K
VWAP?$6.89
Rel. Volume?1.03x
Bid / Ask
Bid?$6.70 × 100
Ask?$7.29 × 100
Spread?$0.59
Midpoint?$7.00
Valuation & Ratios
Market Cap?179.8M
Shares Out?25.8M
Float?24.3M
Float %?94.0%
P/E Ratio?N/A
P/B Ratio?2.36
EPS?-$1.69
Dividend?0.00%
Ex-Dividend?N/A

DTIL is currently priced at $6.97. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Strong Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation side, DTIL appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of May 29, 2026.

News
Profile
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Clinical-Stage Platforms
Employees
66
Market Cap
179.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.precisionbiosciences.com
Listed
2019-03-28
Address
302 EAST PETTIGREW STREET
DURHAM, NC 27701
Phone: 919-314-5512
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
27
Short Sent.?
38
Piotroski F-Score?3/9Weak
Altman Z-Score?-3.47Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?6.24%Elevated
Short Interest?1.5M
Days to Cover?6.5
Free Float24.3M
Avg Daily Volume232.0K
Settlement Date2026-05-15
Financial Health
Current Ratio?14.02Strong
Quick Ratio?14.02Strong
Cash Ratio?12.81Strong
Debt/Equity?0.29Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
67
2.36CHEAP▾
P/S?
Peers
100
S&P
38
3.99FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-2.7CHEAP▾
EV/Sales?
Peers
100
S&P
71
2.28CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-57.3%WEAK▾
ROA?
S&P
3
-30.3%WEAK▾
Cash Flow & Enterprise
FCF?$-58767000
Enterprise Value?$102.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist